Collaborating on Individualized Management Solutions for Pediatric Patients With Moderate-to-Severe Atopic Dermatitis - CME - Guideline Central

CME

Title
Collaborating on Individualized Management Solutions for Pediatric Patients With Moderate-to-Severe Atopic Dermatitis
Link
Description
More than one-third of pediatric patients with atopic dermatitis (AD) have moderate to severe disease, with large areas of dry skin, frequent itching, and skin redness, that strongly impedes daily routines and negatively affects their sleep, mental health, and overall quality of life along with significant impacts on families. Unfortunately, suboptimal assessment of AD in routine clinical practice can lead to delayed diagnosis, underappreciation of disease severity, and delays in treatment initiation, referral to specialists, and treatment intensification. Although basic skin care and topical therapies can be very effective in treating mild cases of AD, patients with moderate to severe disease generally require systemic therapy to achieve long-term disease control. The discovery of the role of type 2 inflammatory pathways in AD has led to new concepts in AD pathogenesis, and subsequently, to novel treatment strategies. Yet evidence indicates that there is discordance between patients’/caregivers’ and clinicians’ perception of severity and disease burden, which may contribute to suboptimal treatment. To improve evaluation, coordination of care, and treatment practices in pediatric patients with AD, clinicians in both primary care and specialty settings must continually assess and adapt to evolving diagnostic and therapeutic strategies to ensure proactive, patient-centric treatment to improve outcomes. To support translation and implementation of the latest evidence into routine clinical practice, this program provides participants with a personalized learning experience. Complete an initial assessment, receive individualized recommendations for education, and access tools and resources to develop an action plan for improving the care of pediatric patients with atopic dermatitis.
Target Audience
This educational activity is designed for pediatric dermatologists, pediatricians, dermatologists, allergists, and NPs/PAs in dermatology, allergy, family medicine, and primary care/pediatric settings.
Learning Objectives
  • Develop coordination of care practices to improve recognition, referral, and patient-centric management of moderate-to-severe atopic dermatitis (AD)
  • Interpret and apply the latest evidence for the systemic treatment of moderate-to-severe AD in pediatric patients
  • Collaborate with patients and caregivers to incorporate patient-reported/caregiver-reported outcomes, preferences, and goals into individualized management plans
  • Develop treatment algorithms to optimally initiate and sequence therapies for pediatric patients with moderate-to-severe AD
Estimated Duration
255 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Pediatrics, Family Medicine, Dermatology, Allergy and Immunology, Primary Care
Keywords
atopic dermatitis (AD)
Disclosures and Disclaimers
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s). This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Accredited Providers
  • Academy for Continued Healthcare Learning (ACHL)
Commercial Support
  • Regeneron Pharmaceuticals, Inc
  • Sanofi US
Activity Expiration Date
March 31, 2027
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit4.25 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.